BrightInsight Announces $101M in Series C Funding led by General Catalyst The Financing will Fuel BrightInsight’s Hypergrowth as the Leading Global Regulated Digital Health Platform for Biopharma and MedtechSAN JOSE, Calif., March 30, 2021 – BrightInsight, Inc.,...
Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage...
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on...
ADDEX ANNOUNCES PRICING OF $10.0 MILLION GLOBAL OFFERING Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS HPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development SOUTH SAN FRANCISCO, Calif., Jan....
HARPOON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares...
Recent Comments